By Dr. Shawn Xu, Executive Director, Boston Innovation Center, Simcere Pharmaceutical Group
I am very honored and excited to stand here to represent Simcere to accept this leadership in community service award. First, I would like to thank CABA (Chinese American Bio-Medical Association) for providing such an excellent and successful event, thank you for honoring Simcere with this prestigious award. It is a recognition of our commitment to advancing the Chinese-American Biomedical Community. I also would like to thank every attendee at the Boston Bio-Forum today. Your support is much valued.
Dr. Xu(right) receives the award from Bo Ying, president of CABA.
Since 2007, CABA has played a leading role in fostering collaborations for the Chinese-American community and the life sciences industry. Simcere is very honored to be a long-term partner of CABA to work together to promote professional interactions in the field of life sciences. Simcere and CABA have co-hosted several professional events in the past. In this coming June 8th, a CABA-Simcere team will join dragon boat competition at the 2019 Boston Dragon Boat Festival. I sincerely invite all of you to come enjoy the festival and watch the competition.
Simcere is a Chinese leading R&D-driven pharmaceutical company, founded in 1995 with a mission to “bring better medicines for patients sooner.” We have over 50 products on the market, 4 GMP manufacturing sites, 3 oversea branches in United States, Europe and Hong Kong with over 5000 employees worked worldwide. Simcere has achieved 30% Annual Growth Rate in last 5 years. In addition, we have diagnosis company-Simcere Diagnosis in Nanjing to provide precision medical solutions in China.
We are committed to our research and development, and dedicate more than 10% of our revenue to R&D every year. We have China’s only State Key Laboratory of Translational Medicine & Innovative Drug Development, and we have research institute in Nanjing and innovation center in Shanghai with over 500 R&D scientists working in China, many of them have overseas experience. So far, we have filed 237 patents. Currently, we are on the way expanding our Chinese R&D team to over 1,000.
We are committed to innovative drug discovery and development for global community. Last year, we have launched our Shanghai innovation Center, which located at Shanghai Pudong medical science park. Currently, I am leading the effort to establish our Innovation Center in Boston. We have signed a 25,000 sqft lab and office space at a brand new building located at Cambridge discovery Park, and we will have total 80-100 R&D scientists work here by next year. Currently, we have multiple openings from entry level to VP level for cell therapy, gene therapy, antibody discovery and business development. In addition, we have multiple openings in shanghai and Nanjing. If you want to have a big stage and platform to play, please join us. We work together to discover and develop high-quality medicines for patients.
I believe Simcere’s growing in Boston and in America will open up many more opportunities for collaboration between Simcere and CABA, between Simcere and all of you here today.
We look forward to continuing the strong partnership with CABA and supporting CABA in its mission to promote science, build a professional platform, and facilitate innovations. Thank you for attention!